User login
WASHINGTON – A promising early Alzheimer’s treatment, a new finding in the brains of migraineurs, and a practice-changing stroke treatment study are the top picks for clinical research being presented at the annual meeting of the American Academy of Neurology, according to Dr. Natalia Rost, vice chair of the AAN Science Committee.
The first is an early-phase clinical study evaluating a new monoclonal antibody in 166 people with prodromal or mild Alzheimer’s disease. The second study evaluated the association between pain threshold and cortical thickness in patients with migraines. The third is a presentation of the MR CLEAN study results from the Netherlands, which compared standard of care versus standard of care plus mechanical embolectomy in 500 patients with acute stroke – a study that Dr. Rost, a stroke neurologist, described in this video interview as “game-changing.” Dr. Rost is associate professor of neurology at Harvard Medical School and associate director of acute stroke services at Massachusetts General Hospital, both in Boston.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WASHINGTON – A promising early Alzheimer’s treatment, a new finding in the brains of migraineurs, and a practice-changing stroke treatment study are the top picks for clinical research being presented at the annual meeting of the American Academy of Neurology, according to Dr. Natalia Rost, vice chair of the AAN Science Committee.
The first is an early-phase clinical study evaluating a new monoclonal antibody in 166 people with prodromal or mild Alzheimer’s disease. The second study evaluated the association between pain threshold and cortical thickness in patients with migraines. The third is a presentation of the MR CLEAN study results from the Netherlands, which compared standard of care versus standard of care plus mechanical embolectomy in 500 patients with acute stroke – a study that Dr. Rost, a stroke neurologist, described in this video interview as “game-changing.” Dr. Rost is associate professor of neurology at Harvard Medical School and associate director of acute stroke services at Massachusetts General Hospital, both in Boston.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WASHINGTON – A promising early Alzheimer’s treatment, a new finding in the brains of migraineurs, and a practice-changing stroke treatment study are the top picks for clinical research being presented at the annual meeting of the American Academy of Neurology, according to Dr. Natalia Rost, vice chair of the AAN Science Committee.
The first is an early-phase clinical study evaluating a new monoclonal antibody in 166 people with prodromal or mild Alzheimer’s disease. The second study evaluated the association between pain threshold and cortical thickness in patients with migraines. The third is a presentation of the MR CLEAN study results from the Netherlands, which compared standard of care versus standard of care plus mechanical embolectomy in 500 patients with acute stroke – a study that Dr. Rost, a stroke neurologist, described in this video interview as “game-changing.” Dr. Rost is associate professor of neurology at Harvard Medical School and associate director of acute stroke services at Massachusetts General Hospital, both in Boston.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT THE AAN 2015 ANNUAL MEETING
